US Pharma MarketingSonoThera raises $125M for non-viral gene therapy approach
SonoThera has secured another $125 million to take its ultrasound-based gene therapy technology into the clinic. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing…
SonoThera has secured another $125 million to take its ultrasound-based gene therapy technology into the clinic.
The company is focused on two lead programs in Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease, and ...
Source: Endpoints News